Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × cositecan × Clear all
NCT00062491 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
46 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡